Opportunity Information: Apply for PAR 16 322
Apply for PAR 16 322
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R24)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.351,.
- This funding opportunity was created on Jun 13, 2016 and posted on Jun 13, 2016.
- Applicants must submit their applications by Sep 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity titled "Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R24)" (Funding Opportunity Number PAR-16-322) is a discretionary NIH grant program under the U.S. Department of Health and Human Services. It supports research in the health arena (CFDA 93.351; the listing also references 93.351 in the source data) and is designed to strengthen the scientific foundations needed to translate stem cell-based approaches into regenerative medicine therapies. The central idea is that better, more informative animal stem cell resources and disease models will make preclinical testing more predictive, improve understanding of stem cell behavior in living systems, and ultimately help move promising therapies toward clinical use.
The program specifically encourages institutions and organizations to propose research that characterizes animal stem cells and improves existing animal models, or creates new ones, that more faithfully reflect human disease conditions relevant to regenerative medicine. In practice, this means applicants are expected to tackle gaps that currently limit the usefulness of animal studies for stem cell therapy development, such as incomplete knowledge of how animal stem cells compare to human stem cells, insufficient tools to track or evaluate transplanted cells, or disease models that do not adequately reproduce key biological features of human disorders.
The initiative highlights three main focus areas. First, it calls for comparative analyses of animal and human stem cells to guide the selection of the most predictive and informative model systems. This emphasis reflects the reality that different species can vary in stem cell biology, immune responses, development, tissue repair mechanisms, and disease progression. Projects in this area would aim to generate data that clarifies similarities and differences across species so researchers can choose models that best match the human condition they are trying to treat, rather than relying on convenience or tradition alone.
Second, the FOA prioritizes development of new technologies for stem cell characterization and transplantation. This can include improved methods to identify, isolate, and profile stem cell populations; tools to monitor cell fate after transplantation; and approaches that make transplantation more reproducible and clinically relevant. Technologies that strengthen measurement and standardization are especially valuable in this space because they can reduce uncertainty in interpreting outcomes and make it easier to compare results across studies, labs, and species.
Third, the opportunity supports improvement of animal disease models specifically for stem cell-based therapeutic applications. The goal is not just to model disease in general, but to create or refine models in ways that make them useful for evaluating stem cell interventions: for example, models that better capture clinically meaningful endpoints, reflect the appropriate tissue microenvironment, incorporate relevant immune or inflammatory components, or enable more rigorous assessment of safety, durability, and functional recovery after treatment.
Eligibility is broad and includes many types of U.S.-based organizations: state, county, and municipal governments; special district governments; independent school districts; public and state-controlled universities; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (excluding institutions of higher education in those categories); for-profit organizations other than small businesses; small businesses; and other entities as allowed under the FOA's additional eligibility language. The funding instrument is a grant, and the administering agency is listed as HHS-NIH (HHS-NIH11 in the provided source data). The announcement was created and posted on June 13, 2016, and the closing date shown is September 7, 2019.
Overall, the opportunity is aimed at building and refining the animal-based experimental platforms that underpin regenerative medicine translation. By improving cross-species stem cell understanding, developing better characterization and transplantation tools, and strengthening disease models that are specifically tailored to testing stem cell therapies, the program is intended to reduce translational risk and accelerate progress toward safe and effective regenerative treatments for human disease.
Frequently Asked Questions (FAQs)
What is the title of this funding opportunity?
The funding opportunity is titled "Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R24)".
What is the Funding Opportunity Number (FOA number)?
The FOA number is PAR-16-322.
Which agency administers this grant program?
This is a discretionary grant program under the U.S. Department of Health and Human Services (HHS), administered by NIH. The administering agency is listed as HHS-NIH (shown as HHS-NIH11 in the provided source data).
What type of funding instrument is used?
The funding instrument is a grant.
What is the CFDA number associated with this opportunity?
The opportunity is associated with CFDA 93.351 (also referenced as 93.351 in the provided source data).
What is the main purpose of this program?
The program supports research intended to strengthen the scientific foundations needed to translate stem cell-based approaches into regenerative medicine therapies. It focuses on building better animal stem cell resources and more informative animal disease models so that preclinical testing is more predictive and stem cell behavior in living systems is better understood.
Why does this FOA focus on improving animal models for regenerative medicine?
The central idea is that more informative animal stem cell resources and disease models can make preclinical testing more predictive, improve understanding of stem cell behavior in vivo, and help move promising regenerative medicine therapies closer to clinical use by reducing translational uncertainty.
What kinds of projects does the FOA encourage?
The FOA encourages projects that characterize animal stem cells and that improve existing animal models or create new animal models that more faithfully reflect human disease conditions relevant to regenerative medicine, specifically in ways that support evaluation of stem cell-based therapeutic approaches.
What gaps or limitations is the program trying to address?
The FOA is aimed at overcoming limitations that reduce the usefulness of animal studies for stem cell therapy development, such as incomplete knowledge of how animal stem cells compare to human stem cells, insufficient tools to track or evaluate transplanted cells, and disease models that do not adequately reproduce key biological features of human disorders.
What are the three main focus areas highlighted in the FOA?
The initiative highlights three main focus areas:
- Comparative analyses of animal and human stem cells to guide selection of predictive model systems
- Development of new technologies for stem cell characterization and transplantation
- Improvement of animal disease models specifically for stem cell-based therapeutic applications
What does "comparative analyses of animal and human stem cells" mean in this FOA?
It refers to research that generates data clarifying similarities and differences between animal and human stem cells. The goal is to help researchers select the most predictive and informative animal model systems for the human conditions they aim to treat, recognizing that different species can vary in stem cell biology, immune responses, development, tissue repair mechanisms, and disease progression.
Why does species selection matter for stem cell-based regenerative medicine?
The FOA emphasizes that different animal species can differ in key areas such as stem cell biology and immune responses. Comparative work can help avoid choosing models based mainly on convenience or tradition, and instead support model selection that better matches the human disease biology and therapeutic context.
What kinds of technology development are encouraged?
The FOA prioritizes development of technologies that improve stem cell characterization and transplantation, including methods to identify, isolate, and profile stem cell populations; tools to monitor cell fate after transplantation; and approaches that make transplantation more reproducible and clinically relevant.
Why does the FOA emphasize measurement and standardization?
Technologies that strengthen measurement and standardization are highlighted because they can reduce uncertainty in interpreting outcomes and make it easier to compare results across studies, laboratories, and species.
What does it mean to improve animal disease models "specifically for stem cell-based therapeutic applications"?
It means improving or creating models not only to represent a disease generally, but to ensure they are useful for evaluating stem cell interventions. Examples described in the FOA include models that better capture clinically meaningful endpoints, reflect the appropriate tissue microenvironment, incorporate relevant immune or inflammatory components, and enable rigorous assessment of safety, durability, and functional recovery after treatment.
What is the ultimate translational goal of the program?
The program aims to reduce translational risk and accelerate progress toward safe and effective regenerative treatments for human disease by strengthening the animal-based experimental platforms that underpin regenerative medicine translation.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S.-based organizations, including:
- State, county, and municipal governments
- Special district governments
- Independent school districts
- Public and state-controlled universities
- Private institutions of higher education
- Federally recognized Native American tribal governments and other tribal organizations
- Public housing authorities / Indian housing authorities
- Nonprofits with and without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories)
- For-profit organizations other than small businesses
- Small businesses
- Other entities as allowed under the FOA's additional eligibility language
Are small businesses eligible?
Yes. Small businesses are listed among the eligible applicant organizations.
Are for-profit organizations eligible?
Yes. For-profit organizations other than small businesses are listed as eligible, and small businesses are also listed separately as eligible.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized Native American tribal governments and other tribal organizations are included in the eligible applicant types.
Are nonprofits eligible?
Yes. Nonprofits with and without 501(c)(3) status are listed as eligible (with the note that institutions of higher education are excluded from those specific nonprofit categories, since higher education eligibility is listed separately).
When was this funding opportunity posted?
The announcement was created and posted on June 13, 2016.
What is the closing date shown for this opportunity?
The closing date shown is September 7, 2019.
What research area does this opportunity support?
It supports research in the health arena focused on stem cell-based regenerative medicine, with an emphasis on improving animal stem cell resources, transplantation/characterization technologies, and animal disease models to support preclinical testing and translation.
Is this opportunity aimed at basic research, translational research, or both?
Based on the provided description, it is designed to strengthen foundational science and tools in ways that directly support translation of stem cell-based approaches into regenerative medicine therapies, especially by improving the predictive value of preclinical animal studies.
Browse more opportunities from the same category: Health
Next opportunity: Mechanisms for speciess responses to climate change: are there biological response thresholds?
Previous opportunity: Internet Freedom Core Support for Anti-Censorship Technology
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 322
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 322) also looked into and applied for these:
| Funding Opportunity |
|---|
| Bold New Bioengineering Methods and Approaches for Heart, Lung, Blood and Sleep Disorders and Diseases (R21) Apply for RFA HL 17 015 Funding Number: RFA HL 17 015 Agency: HHS-NIH11 Category: Health Funding Amount: $150,000 |
| Limited Competition: NIDCR Supplements to NCATS CTSA Programs for Scholars Pursing Dental, Oral and Craniofacial Clinical and Translational Research Career Development (Admin Supp) Apply for RFA DE 17 008 Funding Number: RFA DE 17 008 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Guidance for Supplemental CDC/NCCDPHP/BRFSS Funding Opportunity Announcement (FOA) CDC-RFA-DP15-15130201SUPPPPHF16 Behavioral Risk Factor Surveillance System (BRFSS) Apply for CDC RFA DP15 15130201SUPPPPHF16 Funding Number: CDC RFA DP15 15130201SUPPPPHF16 Agency: HHS-CDC-NCCDPHP Category: Health Funding Amount: $160,000 |
| Limited Competition: Administrative Supplements to Enhance Network Capacity: Collaborative Opportunities for the CTSA Program (Admin Supp) Apply for PA 16 328 Funding Number: PA 16 328 Agency: HHS-NIH11 Category: Health Funding Amount: $300,000 |
| Embassy Conakry Ebola-Related Projects Apply for CKY PAS FY16 002 Funding Number: CKY PAS FY16 002 Agency: DOS-AF Category: Health Funding Amount: $10,000 |
| National HIV Surveillance System (NHSS) Apply for CDC RFA PS13 130205CONT17 Funding Number: CDC RFA PS13 130205CONT17 Agency: HHS-CDC-NCHHSTP Category: Health Funding Amount: Case Dependent |
| Science of Behavior Change: Use-inspired Basic Research to Optimize Behavior Change Interventions and Outcomes (Admin Supp) Apply for PA 16 334 Funding Number: PA 16 334 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| National Accessibility Technical Assistance and Support Apply for P16AS00252 Funding Number: P16AS00252 Agency: DOI-NPS Category: Health Funding Amount: $100,000 |
| Strengthening of Public Health Programs to address Communicable and Non-Communicable Diseases in the Republic of Kenya including the Presidents Emergency Plan for AIDS Relief (PEPFAR). Apply for CDC RFA GH16 1703 Funding Number: CDC RFA GH16 1703 Agency: HHS-CDC-CGH Category: Health Funding Amount: Case Dependent |
| Service Area Competition Apply for HRSA 17 050 Funding Number: HRSA 17 050 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| NHLBI Pilot Program to Provide Regulatory Support to SBIR/STTR Awardees Developing Medical Devices (Diagnostics and Therapeutics) (Admin Supp) Apply for PA 16 335 Funding Number: PA 16 335 Agency: HHS-NIH11 Category: Health Funding Amount: $5,000 |
| Urban Indian Education and Research Organization Cooperative Agreement Program Apply for HHS 2016 IHS UIHP3 0001 Funding Number: HHS 2016 IHS UIHP3 0001 Agency: HHS-IHS Category: Health Funding Amount: $800,000 |
| Planning Grant for NINDS Morris K. Udall Parkinson's Disease Research Center Without Walls (R34) Apply for RFA NS 16 024 Funding Number: RFA NS 16 024 Agency: HHS-NIH11 Category: Health Funding Amount: $150,000 |
| Native American Independent Living Demonstration Project Apply for HHS 2016 ACL AOD IL 0184 Funding Number: HHS 2016 ACL AOD IL 0184 Agency: HHS-ACL Category: Health Funding Amount: $250,000 |
| Tuberculosis regional Training and Medical Consultation Centers,National Center for HIV, Hepatitis, Sexually Transmitted Diseases and Tuberculosis Apply for CDC RFA PS13 130404CONT17 Funding Number: CDC RFA PS13 130404CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - NCHHSTP Category: Health Funding Amount: Case Dependent |
| Pediatric Audiology Competitive Supplement to Leadership Education in Neurodevelopmental and Related Disabilities (LEND) Apply for HRSA 16 190 Funding Number: HRSA 16 190 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $80,000 |
| Service Area Competition Apply for HRSA 17 051 Funding Number: HRSA 17 051 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Office of Clinical and Preventive Services: National HIV Program; HIV/AIDS Prevention and Engagement in Care Apply for HHS 2016 IHS OCPS HIV 0001 Funding Number: HHS 2016 IHS OCPS HIV 0001 Agency: Department of Health and Human Services, Indian Health Service Category: Health Funding Amount: $100,000 |
| Division of Behavioral Health, Office of Clinical and Preventive Services, Methamphetamine and Suicide Prevention Initiative - Generation Indigenous (Gen-I) Initiative Support - New Apply for HHS 2016 IHS MSPI 0001 Funding Number: HHS 2016 IHS MSPI 0001 Agency: Department of Health and Human Services, Indian Health Service Category: Health Funding Amount: $300,000 |
| A National Coalition to Enhance STD/HIV Prevention through Promotion of a Holistic Approach to Health and Wellness Apply for CDC RFA PS11 11120501SUPP16 Funding Number: CDC RFA PS11 11120501SUPP16 Agency: Department of Health and Human Services, Centers for Disease Control - NCHHSTP Category: Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 322", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.